Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Butrus Atrash

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Journal of Chemical Information and Modeling|June 10, 2015
MOARF, an Integrated Workflow for Multiobjective Optimization: Implementation, Synthesis, and Biological EvaluationNicholas C Firth, Butrus Atrash, Nathan Brown, et al.
Angewandte Chemie (International Ed. in English)|March 10, 2001
Revolutionizing Resin Handling for Combinatorial SynthesisButrus Atrash, Mark Bradley, Ryzard Kobylecki, et al.
The Biochemical Journal|January 14, 2010
Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug designCharlotte A Dodson, Magda Kosmopoulou, Mark W Richards, et al.
Plos One|July 10, 2020
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancerSheelagh Frame, Chiara Saladino, Craig MacKay, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 7, 2019
Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology speciesFrancesca L Wood, Sam Shepherd, Angela Hayes, et al.
Bioorganic & Medicinal Chemistry Letters|September 14, 2010
Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cellsNathalie Bouloc, Jonathan M Large, Magda Kosmopoulou, et al.
Molecular Cancer Therapeutics|September 3, 2011
The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivoAmir Faisal, Lynsey Vaughan, Vassilios Bavetsias, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 13, 2016
Pyrido[3,4-d]pyrimidin-4(3H)-one metabolism mediated by aldehyde oxidase is blocked by C2-substitutionAngela Hayes, N Yi Mok, Manjuan Liu, et al.
Bioorganic & Medicinal Chemistry Letters|August 23, 2015
7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituentVassilios Bavetsias, Yolanda Pérez-Fuertes, Patrick J McIntyre, et al.
Bioorganic & Medicinal Chemistry|October 11, 2011
Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitorsStuart C Wilson, Butrus Atrash, Clare Barlow, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal of Chemical Information and Modeling|June 10, 2015
MOARF, an Integrated Workflow for Multiobjective Optimization: Implementation, Synthesis, and Biological EvaluationNicholas C Firth, Butrus Atrash, Nathan Brown, et al.
Angewandte Chemie (International Ed. in English)|March 10, 2001
Revolutionizing Resin Handling for Combinatorial SynthesisButrus Atrash, Mark Bradley, Ryzard Kobylecki, et al.
The Biochemical Journal|January 14, 2010
Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug designCharlotte A Dodson, Magda Kosmopoulou, Mark W Richards, et al.
Plos One|July 10, 2020
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancerSheelagh Frame, Chiara Saladino, Craig MacKay, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 7, 2019
Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology speciesFrancesca L Wood, Sam Shepherd, Angela Hayes, et al.
Bioorganic & Medicinal Chemistry Letters|September 14, 2010
Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cellsNathalie Bouloc, Jonathan M Large, Magda Kosmopoulou, et al.
Molecular Cancer Therapeutics|September 3, 2011
The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivoAmir Faisal, Lynsey Vaughan, Vassilios Bavetsias, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 13, 2016
Pyrido[3,4-d]pyrimidin-4(3H)-one metabolism mediated by aldehyde oxidase is blocked by C2-substitutionAngela Hayes, N Yi Mok, Manjuan Liu, et al.
Bioorganic & Medicinal Chemistry Letters|August 23, 2015
7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituentVassilios Bavetsias, Yolanda Pérez-Fuertes, Patrick J McIntyre, et al.
Bioorganic & Medicinal Chemistry|October 11, 2011
Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitorsStuart C Wilson, Butrus Atrash, Clare Barlow, et al.
Pageof 2